Guillaume E. Beranger

Team1, Equipe Labellisée Ligue 2020 And Equipe Labellisée ARC 2019
Nice, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity.

Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity.

Journal: Molecular cancer

Published: January 28, 2021

ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity.

ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity.

Journal: Molecular cancer

Published: October 15, 2020

Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma.

Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma.

Journal: Pigment cell & melanoma research

Published: August 20, 2020

Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease.

Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease.

Journal: Cell death and differentiation

Published: August 04, 2020

Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma.

Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma.

Journal: Cancer research

Published: June 22, 2020

FBXO32 links ubiquitination to epigenetic reprograming of melanoma cells.

FBXO32 links ubiquitination to epigenetic reprograming of melanoma cells.

Journal: Cell death and differentiation

Published: May 25, 2020

Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies.

Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies.

Journal: Cell death & disease

Published: April 08, 2020

CLEC12B Decreases Melanoma Proliferation by Repressing Signal Transducer and Activator of Transcription 3.

CLEC12B Decreases Melanoma Proliferation by Repressing Signal Transducer and Activator of Transcription 3.

Journal: The Journal of investigative dermatology

Published: April 02, 2020

Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo.

Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo.

Journal: Nature communications

Published: September 27, 2018

Uncovering and deciphering the pro-invasive role of HACE1 in melanoma cells.

Uncovering and deciphering the pro-invasive role of HACE1 in melanoma cells.

Journal: Cell death and differentiation

Published: November 30, 2017

Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016.

Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016.

Journal: Annales de dermatologie et de venereologie

Published: November 05, 2017

Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.

Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.

Journal: Genes & development

Published: August 08, 2017

Showing 1-12 of 24

Last Updated: 09/26/2026